Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU

09:51 EDT 11 Oct 2019 | Elsevier Business Intelligence

MolMed decided to the withdraw the drug's conditional marketing authorization after Phase III clinical trial results show...

Original Article: Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU


More From BioPortfolio on "Disappointing End For MolMed’s Zalmoxis Cell Therapy In EU"

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...